Glenmark launches Nebzmart GFB Smartules and Glenmark Airz FB Smartules

25 Nov 2025 Evaluate

Glenmark Pharmaceuticals has launched Nebzmart GFB Smartules and Glenmark Airz FB Smartules, the world’s first nebulized, fixed-dose triple therapy for the treatment of Chronic Obstructive Pulmonary Disease (COPD). Both products combine three proven medicines - Glycopyrronium, Formoterol, and Budesonide - to reduce airway obstruction, inflammation, and improve lung function and symptom control. As a single, easy-to-use nebulized therapy, it minimizes the burden of multiple medications. This marks a breakthrough as a new standard of care for COPD patients, especially those who struggle with using Metered Dose Inhalers (MDI) or Dry Powder Inhalers (DPI).

In a clinical study conducted in India, this nebulized triple therapy demonstrated rapid improvement in lung function and better control of breathlessness (dyspnea) among patients. The treatment was well tolerated and demonstrated a good safety profile, offering patients a simpler and more effective way to manage COPD.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.


Glenmark Pharma Share Price

1961.50 -12.65 (-0.64%)
05-Dec-2025 14:48 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1801.35
Dr. Reddys Lab 1275.30
Cipla 1517.15
Zydus Lifesciences 930.00
Lupin 2090.45
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×